IN2013MU01696A - - Google Patents

Download PDF

Info

Publication number
IN2013MU01696A
IN2013MU01696A IN1696MU2013A IN2013MU01696A IN 2013MU01696 A IN2013MU01696 A IN 2013MU01696A IN 1696MU2013 A IN1696MU2013 A IN 1696MU2013A IN 2013MU01696 A IN2013MU01696 A IN 2013MU01696A
Authority
IN
India
Prior art keywords
pharmaceutical composition
present
low dose
dose pharmaceutical
disclosed
Prior art date
Application number
Other languages
English (en)
Inventor
Geena Malhotra
Shrinivas Madhukar Purandare
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP14731760.6A priority Critical patent/EP2994131A1/en
Priority to IN1696MU2013 priority patent/IN2013MU01696A/en
Application filed by Cipla Ltd filed Critical Cipla Ltd
Priority to RU2015149544A priority patent/RU2015149544A/ru
Priority to CN201480038832.0A priority patent/CN105377256A/zh
Priority to CA2911671A priority patent/CA2911671A1/en
Priority to US14/890,235 priority patent/US20160120847A1/en
Priority to MX2015015553A priority patent/MX2015015553A/es
Priority to JP2016512416A priority patent/JP2016518398A/ja
Priority to PE2015002380A priority patent/PE20151934A1/es
Priority to AP2015008875A priority patent/AP2015008875A0/xx
Priority to ZA2014/03276A priority patent/ZA201403276B/en
Priority to AU2014264421A priority patent/AU2014264421A1/en
Priority to PCT/GB2014/051400 priority patent/WO2014181108A1/en
Priority to BR112015028257A priority patent/BR112015028257A2/pt
Priority to SG11201509308TA priority patent/SG11201509308TA/en
Publication of IN2013MU01696A publication Critical patent/IN2013MU01696A/en
Priority to PH12015502557A priority patent/PH12015502557A1/en
Priority to ECIEPI201551434A priority patent/ECSP15051434A/es
Priority to US15/047,091 priority patent/US20160158202A1/en
Priority to HK16103262.7A priority patent/HK1215191A1/zh
Priority to US15/291,728 priority patent/US20170095453A1/en
Priority to US15/650,195 priority patent/US20170312254A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
IN1696MU2013 2010-10-01 2014-05-08 IN2013MU01696A (es)

Priority Applications (21)

Application Number Priority Date Filing Date Title
ZA2014/03276A ZA201403276B (en) 2013-05-10 2014-05-08 Low dose pharmaceutical composition
AP2015008875A AP2015008875A0 (en) 2013-05-10 2014-05-08 Low dose pharmaceutical composition
RU2015149544A RU2015149544A (ru) 2013-05-10 2014-05-08 Низкодозовая фармацевтическая композиция
CN201480038832.0A CN105377256A (zh) 2013-05-10 2014-05-08 低剂量药物组合物
CA2911671A CA2911671A1 (en) 2013-05-10 2014-05-08 Low dose pharmaceutical composition
US14/890,235 US20160120847A1 (en) 2013-05-10 2014-05-08 Low Dose Pharmaceutical Composition
IN1696MU2013 IN2013MU01696A (es) 2013-05-10 2014-05-08
JP2016512416A JP2016518398A (ja) 2013-05-10 2014-05-08 低用量医薬組成物
AU2014264421A AU2014264421A1 (en) 2013-05-10 2014-05-08 Low dose pharmaceutical composition
EP14731760.6A EP2994131A1 (en) 2013-05-10 2014-05-08 Low dose pharmaceutical composition
MX2015015553A MX2015015553A (es) 2013-05-10 2014-05-08 Composicion farmceutica de dosis baja.
PE2015002380A PE20151934A1 (es) 2013-05-10 2014-05-08 Composicion farmaceutica de dosis baja
PCT/GB2014/051400 WO2014181108A1 (en) 2013-05-10 2014-05-08 Low dose pharmaceutical composition
BR112015028257A BR112015028257A2 (pt) 2013-05-10 2014-05-08 composição farmacêutica de baixa dose, método para tratar sobrecarga de ferro crônica, método para tratar toxicidade por chumbo, processo para preparar uma composição farmacêutica de baixa dose e processo
SG11201509308TA SG11201509308TA (en) 2013-05-10 2014-05-08 Low dose pharmaceutical composition
PH12015502557A PH12015502557A1 (en) 2013-05-10 2015-11-10 Low dose pharmaceutical composition
ECIEPI201551434A ECSP15051434A (es) 2013-05-10 2015-12-10 Composición farmacéutica de dosis baja
US15/047,091 US20160158202A1 (en) 2010-10-01 2016-02-18 Low Dose Pharmaceutical Composition
HK16103262.7A HK1215191A1 (zh) 2013-05-10 2016-03-21 低劑量醫藥組合物
US15/291,728 US20170095453A1 (en) 2013-05-10 2016-10-12 Low Dose Pharmaceutical Composition
US15/650,195 US20170312254A1 (en) 2010-10-01 2017-07-14 Low Dose Pharmaceutical Composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1696MU2013 IN2013MU01696A (es) 2013-05-10 2014-05-08

Publications (1)

Publication Number Publication Date
IN2013MU01696A true IN2013MU01696A (es) 2015-06-26

Family

ID=50979804

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1696MU2013 IN2013MU01696A (es) 2010-10-01 2014-05-08

Country Status (18)

Country Link
US (4) US20160120847A1 (es)
EP (1) EP2994131A1 (es)
JP (1) JP2016518398A (es)
CN (1) CN105377256A (es)
AP (1) AP2015008875A0 (es)
AU (1) AU2014264421A1 (es)
BR (1) BR112015028257A2 (es)
CA (1) CA2911671A1 (es)
EC (1) ECSP15051434A (es)
HK (1) HK1215191A1 (es)
IN (1) IN2013MU01696A (es)
MX (1) MX2015015553A (es)
PE (1) PE20151934A1 (es)
PH (1) PH12015502557A1 (es)
RU (1) RU2015149544A (es)
SG (1) SG11201509308TA (es)
WO (1) WO2014181108A1 (es)
ZA (1) ZA201403276B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3310354A4 (en) * 2015-06-17 2018-12-12 Dispersol Technologies, LLC Improved formulations of deferasirox and methods of making the same
RU2616267C1 (ru) * 2016-01-25 2017-04-13 Закрытое Акционерное Общество "БИОКОМ" Твердая лекарственная форма индинавира немедленного высвобождения и способ ее получения
WO2017158559A1 (en) * 2016-03-17 2017-09-21 Lupin Limited Compositions of deferasirox
CN105853367B (zh) * 2016-05-10 2019-07-12 广州加德恩医药有限公司 地拉罗司固体分散体的制备方法及其药物制剂
EP3481390A4 (en) * 2016-07-05 2020-03-04 Jubilant Generics Limited PHARMACEUTICAL COMPOSITION WITH IMMEDIATE RELEASE OF IRON CHELATE IMAGERS
CZ2017255A3 (cs) * 2017-05-04 2018-11-14 Zentiva, K.S. Filmem potažené tablety Deferasiroxu
EP3639854A4 (en) 2017-06-16 2021-03-03 The Doshisha MTOR INHIBITIVE MEDICINAL PRODUCT FOR THE TREATMENT OR PREVENTION OF OPHTHALMIC SYMPTOMS, DISORDERS, OR DISEASES AND USE THEREOF
WO2018230713A1 (ja) * 2017-06-16 2018-12-20 学校法人同志社 カスパーゼ阻害活性を有する化合物、これらの化合物を含む、角膜内皮の症状、障害または疾患を治療または予防するための医薬およびその応用
SG11202003153TA (en) * 2017-10-25 2020-05-28 Chiesi Farm Spa Delayed release deferiprone tablets and methods of using the same
CN109646423A (zh) * 2018-12-03 2019-04-19 泓博元生命科技（深圳）有限公司 含nadh的生物高分子纳米球及其制备方法与应用
CN115400088B (zh) * 2022-09-06 2023-07-07 上海奥科达医药科技股份有限公司 一种地拉罗司药物组合物及其制备方法
CN115154428B (zh) * 2022-09-06 2023-01-10 上海奥科达医药科技股份有限公司 一种地拉罗司药物组合物及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW533205B (en) * 1996-06-25 2003-05-21 Novartis Ag Substituted 3,5-diphenyl-l,2,4-triazoles and their pharmaceutical composition
GB0223978D0 (en) 2002-10-15 2002-11-20 Novartis Ag Organic compound
GB0408078D0 (en) 2004-04-08 2004-05-12 Novartis Ag Organic compounds
WO2007045445A1 (en) 2005-10-19 2007-04-26 Novartis Ag Dispersible tablets comprising deferasirox
WO2009016359A1 (en) * 2007-07-27 2009-02-05 Pliva Hrvatska D.O.O. New forms of deferasirox
US20090142395A1 (en) * 2007-11-19 2009-06-04 Uri Zadok Deferasirox pharmaceutical compositions
WO2010035282A1 (en) 2008-09-24 2010-04-01 Matrix Laboratories Limited Pharmaceutical compositions comprising deferasirox
RU2589842C2 (ru) * 2010-10-01 2016-07-10 Сипла Лимитед Фармацевтическая композиция
US20140220017A1 (en) * 2011-09-23 2014-08-07 Universitat Stuttgart Serum half-life extension using igbd

Also Published As

Publication number Publication date
ECSP15051434A (es) 2017-05-31
US20160158202A1 (en) 2016-06-09
WO2014181108A1 (en) 2014-11-13
JP2016518398A (ja) 2016-06-23
PE20151934A1 (es) 2015-12-26
US20170312254A1 (en) 2017-11-02
SG11201509308TA (en) 2015-12-30
MX2015015553A (es) 2016-06-17
BR112015028257A2 (pt) 2017-07-25
EP2994131A1 (en) 2016-03-16
CN105377256A (zh) 2016-03-02
RU2015149544A (ru) 2017-06-16
AU2014264421A1 (en) 2015-12-03
US20170095453A1 (en) 2017-04-06
AP2015008875A0 (en) 2015-11-30
PH12015502557A1 (en) 2016-02-22
US20160120847A1 (en) 2016-05-05
HK1215191A1 (zh) 2016-08-19
ZA201403276B (en) 2015-07-29
CA2911671A1 (en) 2014-11-13

Similar Documents

Publication Publication Date Title
IN2013MU01696A (es)
PH12016500024A1 (en) Bromodomain inhibitor
PH12016500871A1 (en) Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
PH12016501790B1 (en) Pharmaceutical compositions of therapeutically active compounds
PH12016501788B1 (en) Pharmaceutical compositions of therapeutically active compounds
IL258854A (en) Preparations containing cannabidiol and secondary medicinal agents for cancer treatment
IN2014DN10670A (es)
PH12016502352A1 (en) Pharmaceutical composition
IN2013MU03583A (es)
TW201613578A (en) Pharmaceutical combinations
IN2014MN02236A (es)
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
NZ716765A (en) Pharmaceutical combinations for the treatment of cancer
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2015013755A (es) Formulacion farmaceutica para uso en el tratamiento y/o prevencion de restenosis.
MX2019012522A (es) Compuestos y metodos terapeuticos.
MX2018006631A (es) Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas.
MX2018015240A (es) Composiciones que comprenden timolol y su uso en el tratamiento de rosacea mediante administracion topica.
MX365096B (es) Uso de paricalcitol en el tratamiento de la anemia inflamatoria.
IN2013MU02015A (es)
IN2014DE00818A (es)